Judy Mary Cheng, MD
Hematology/Oncology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Zuckerberg San Francisco General Hosp & Trauma Ctr. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Cheng’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A76724 · Current
Licensed to practise in California · since 2001 · expires 2027-08-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Zuckerberg San Francisco General Hosp & Trauma CtrSan Francisco, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of San Francisco Health Network, which runs 2 hospitalsPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.449, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.37, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.538, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Zuckerberg San Francisco General Hosp & Trauma Ctr
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.37 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.538 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 667 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.76 to 1.49) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.34 (147.34 to 243.34) · 76 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.5 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 214 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 261 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,351 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.5) · 4,709 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.19 to 0.59) · 4,644 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.34 (2.11 to 6.56) · 795 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.28) · 234 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.85 (1.33 to 4.38) · 861 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.95 (0.25 to 17.64) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6 (2.01 to 9.98) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 167 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.79 (0.08 to 1.49) · 4,129 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.709 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.769 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 41 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 75.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.3 (8.3 to 15.1) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 132 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.4 to 17.9) · 966 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.7) · 88 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,644 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$3,073
Medicare paid this office $3,073 for 19 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
19 Original Medicare patients in 2024. Average age 71 · Health risk score 2.58. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 68%.
The office billed $16,406, Medicare allowed $3,850 and paid $3,073; for 26 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 19 | 26 | 71 | 2.58 | $16,406 | $3,073 |
| 2023 | 17 | 22 | 68 | 2.49 | $12,192 | $2,334 |
| 2022 | 30 | 47 | 68 | 2.48 | $19,906 | $3,655 |
| 2021 | 21 | 41 | 72 | 3.12 | $16,654 | $3,220 |
| 2020 | 77 | 114 | 71 | 2.32 | $47,200 | $5,884 |
| 2019 | 71 | 84 | 68 | 2.09 | $54,196 | $7,276 |
| 2018 | 39 | 51 | 69 | 2.18 | $27,610 | $5,179 |
| 2017 | 20 | 28 | 65 | 2.29 | $16,590 | $3,074 |
| 2016 | 29 | 46 | 67 | 2.81 | $22,142 | $4,197 |
| 2015 | 19 | 27 | 62 | 2.68 | $16,569 | $3,290 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,073 | $63 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,056 | $81 |
2020: 2 services
| Telephone medical discussion with physician, 11-20 minutes | 21 | $781 | $36 |
| Return visit (30+ min) | 22 | $439 | $20 |
2019: 3 services
| Return visit (30+ min) | 23 | $1,679 | $70 |
| Long return visit (40+ min) | 13 | $1,477 | $98 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,064 | $89 |
2018: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,248 | $173 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,110 | $85 |
2016: 1 service
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,208 | $86 |
Medicaid work
$502,747 in 2024
Medicaid paid $502,747 for 8,092 billed services this clinician did in 2024, up to 116 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,405 | $476,461 |
| COMPREHENSIVE METABOLIC PANEL | 554 | $6,974 |
| OFF/OP EST MAY X REQ PHY/QHP | 1,310 | $5,305 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 543 | $4,941 |
| CT ABDOMEN & PELVIS W/CONTRAST MATERIAL | 12 | $4,281 |
| DIAGNOSTIC COMPUTED TOMOGRAPHY THORAX W/CONTRAST | 12 | $2,922 |
| Return visit (30+ min) | 290 | $1,330 |
| Short return visit (20+ min) | 217 | $533 |
| Introduction of needle or intracatheter, vein | 540 | $0 |
| Measurement of magnesium | 24 | $0 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 20 | $0 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 18 | $0 |
| 2024 | 8,092 | 25 | 116 | $502,747 |
| 2023 | 5,516 | 16 | 88 | $362,836 |
| 2022 | 3,740 | 17 | 73 | $250,182 |
| 2021 | 4,510 | 17 | 81 | $304,874 |
| 2020 | 1,872 | 13 | 60 | $154,835 |
| 2019 | 1,091 | 5 | 44 | $148,857 |
| 2018 | 758 | 4 | 64 | $189,977 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,108 | $356,642 |
| DIAGNOSTIC COMPUTED TOMOGRAPHY THORAX W/CONTRAST | 13 | $3,589 |
| Return visit (30+ min) | 526 | $1,100 |
| OFF/OP EST MAY X REQ PHY/QHP | 956 | $963 |
| Short return visit (20+ min) | 253 | $541 |
| Introduction of needle or intracatheter, vein | 302 | $0 |
| COMPREHENSIVE METABOLIC PANEL | 413 | $0 |
| Measurement of magnesium | 15 | $0 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 395 | $0 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 285 | $0 |
| Infusion, normal saline solution , 1000 cc | 181 | $0 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 38 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 768 | $246,694 |
| Return visit (30+ min) | 240 | $651 |
| DIAGNOSTIC COMPUTED TOMOGRAPHY THORAX W/CONTRAST | 17 | $603 |
| Short return visit (20+ min) | 387 | $579 |
| CT ABDOMEN & PELVIS W/CONTRAST MATERIAL | 12 | $568 |
| OFF/OP EST MAY X REQ PHY/QHP | 684 | $512 |
| COMPREHENSIVE METABOLIC PANEL | 191 | $365 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 194 | $210 |
| Introduction of needle or intracatheter, vein | 205 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 39 | $0 |
| Measurement of magnesium | 19 | $0 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 139 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 941 | $299,632 |
| Return visit (30+ min) | 335 | $1,237 |
| DIAGNOSTIC COMPUTED TOMOGRAPHY THORAX W/CONTRAST | 28 | $1,137 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 386 | $817 |
| CT ABDOMEN & PELVIS W/CONTRAST MATERIAL | 25 | $771 |
| COMPREHENSIVE METABOLIC PANEL | 182 | $510 |
| Short return visit (20+ min) | 209 | $462 |
| OFF/OP EST MAY X REQ PHY/QHP | 744 | $309 |
| Introduction of needle or intracatheter, vein | 231 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 233 | $0 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 181 | $0 |
| Long return visit (40+ min) | 18 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 517 | $153,514 |
| Return visit (30+ min) | 243 | $738 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 197 | $510 |
| OFF/OP EST MAY X REQ PHY/QHP | 256 | $73 |
| Introduction of needle or intracatheter, vein | 50 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 76 | $0 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 54 | $0 |
| Short return visit (20+ min) | 26 | $0 |
| Infusion, normal saline solution , 1000 cc | 45 | $0 |
| Infusion, normal saline solution, 250 cc | 18 | $0 |
| Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 24 | $0 |
| Service | 344 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 485 | $146,980 |
| Return visit (30+ min) | 256 | $1,506 |
| Short return visit (20+ min) | 36 | $200 |
| OFF/OP EST MAY X REQ PHY/QHP | 103 | $170 |
| Service | 211 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 615 | $187,947 |
| Short return visit (20+ min) | 81 | $1,615 |
| Return visit (30+ min) | 50 | $318 |
| Long return visit (40+ min) | 12 | $96 |
Drugs they prescribed that Part D paid
$4,009,984
Pharmacies billed $4,009,984 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (26 of 717) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
473 generic and 244 brand-name prescriptions · $4,009,984 in drug cost · 13 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pomalyst | 32 | $781,180 | $24,412 |
| Revlimid | 36 | $601,180 | $16,699 |
| Jakafi | 24 | $398,859 | $16,619 |
| Tagrisso | 21 | $319,558 | $15,217 |
| Imbruvica | 18 | $293,363 | $16,298 |
See all 20 drugs
| Pomalyst | 32 | $781,180 | $24,412 |
| Revlimid | 36 | $601,180 | $16,699 |
| Jakafi | 24 | $398,859 | $16,619 |
| Tagrisso | 21 | $319,558 | $15,217 |
| Imbruvica | 18 | $293,363 | $16,298 |
| Lorbrena | 12 | $244,497 | $20,375 |
| Tasigna | 12 | $227,928 | $18,994 |
| Abiraterone Acetate | 45 | $189,367 | $4,208 |
| Erleada | 12 | $157,637 | $13,136 |
| Zykadia | 11 | $93,361 | $8,487 |
| Imatinib Mesylate | 42 | $78,482 | $1,869 |
| Lamivudine Hbv | 13 | $3,563 | $274 |
| Entecavir | 14 | $3,205 | $229 |
| Anastrozole | 46 | $672 | $15 |
| Hydroxyurea | 25 | $497 | $20 |
| Ondansetron | 31 | $333 | $11 |
| Prednisone | 48 | $240 | $5 |
| Dexamethasone | 29 | $208 | $7 |
| Oxycodone | 19 | $159 | $8 |
| Olanzapine | 14 | $67 | $5 |
Year by year
| 2024 | 717 | 120 | 4% (26) | 34% | $4,009,984 |
| 2023 | 579 | 89 | 6% (34) | 34% | $3,588,285 |
| 2022 | 442 | 90 | 5% (21) | 32% | $2,065,578 |
| 2021 | 484 | 88 | 15% (71) | 25% | $1,750,527 |
| 2020 | 507 | 75 | 13% (64) | None | $1,573,873 |
| 2019 | 472 | 68 | 10% (45) | 24% | $849,737 |
| 2018 | 452 | 76 | 9% (41) | 23% | $1,174,852 |
| 2017 | 383 | 70 | 9% (36) | 28% | $1,237,537 |
| 2016 | 254 | 55 | 8% (21) | None | $690,050 |
| 2015 | 224 | 26 | None | 36% | $346,896 |
| 2014 | 201 | 21 | None | 32% | $141,188 |
| 2013 | 141 | 17 | None | 42% | $85,831 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Pomalyst | 33 | $758,526 | $22,986 |
| Revlimid | 28 | $472,189 | $16,864 |
| Jakafi | 25 | $471,555 | $18,862 |
| Abiraterone Acetate | 46 | $243,270 | $5,288 |
| Imbruvica | 13 | $218,050 | $16,773 |
| Tagrisso | 11 | $199,669 | $18,152 |
| Imatinib Mesylate | 41 | $64,206 | $1,566 |
| Lamivudine Hbv | 31 | $7,313 | $236 |
| Anastrozole | 20 | $1,807 | $90 |
| Hydroxyurea | 15 | $671 | $45 |
| Dexamethasone | 24 | $360 | $15 |
| Prednisone | 37 | $309 | $8 |
| Ondansetron | 24 | $286 | $12 |
| Oxycodone | 16 | $224 | $14 |
2022: 13 drugs
| Pomalyst | 29 | $616,849 | $21,271 |
| Jakafi | 24 | $429,696 | $17,904 |
| Revlimid | 19 | $307,852 | $16,203 |
| Erlotinib | 11 | $46,347 | $4,213 |
| Imatinib Mesylate | 29 | $41,264 | $1,423 |
| Eliquis | 11 | $6,161 | $560 |
| Lamivudine Hbv | 11 | $3,804 | $346 |
| Anastrozole | 23 | $1,209 | $53 |
| Loperamide | 25 | $685 | $27 |
| Ondansetron | 24 | $626 | $26 |
| Hydroxyurea | 22 | $495 | $22 |
| Oxycodone | 13 | $421 | $32 |
| Dexamethasone | 22 | $265 | $12 |
2021: 12 drugs
| Pomalyst | 17 | $335,892 | $19,758 |
| Revlimid | 12 | $217,106 | $18,092 |
| Jakafi | 13 | $209,948 | $16,150 |
| Imbruvica | 11 | $162,815 | $14,801 |
| Imatinib Mesylate | 30 | $162,625 | $5,421 |
| Oxycodone | 42 | $1,261 | $30 |
| Anastrozole | 40 | $1,150 | $29 |
| Hydroxyurea | 24 | $443 | $18 |
| Ondansetron | 21 | $388 | $18 |
| Hydrocodone-Acetaminophen | 14 | $383 | $27 |
| Morphine Sulfate Er | 15 | $366 | $24 |
| Dexamethasone | 23 | $247 | $11 |
2020: 14 drugs
| Revlimid | 17 | $360,811 | $21,224 |
| Pomalyst | 14 | $268,373 | $19,169 |
| Piqray | 12 | $204,638 | $17,053 |
| Jakafi | 13 | $190,127 | $14,625 |
| Imatinib Mesylate | 32 | $158,884 | $4,965 |
| Promacta | 12 | $80,031 | $6,669 |
| Exemestane | 14 | $6,819 | $487 |
| Oxycodone | 33 | $1,138 | $34 |
| Anastrozole | 61 | $925 | $15 |
| Morphine Sulfate Er | 16 | $459 | $29 |
| Dexamethasone | 20 | $338 | $17 |
| Ondansetron | 17 | $220 | $13 |
| Hydrocodone-Acetaminophen | 14 | $179 | $13 |
| Sertraline | 18 | $86 | $5 |
2019: 10 drugs
| Imatinib Mesylate | 37 | $164,420 | $4,444 |
| Xarelto | 18 | $8,835 | $491 |
| Entecavir | 13 | $1,491 | $115 |
| Anastrozole | 77 | $1,260 | $16 |
| Oxycodone | 18 | $854 | $47 |
| Raloxifene | 11 | $663 | $60 |
| Hydrocodone-Acetaminophen | 16 | $382 | $24 |
| Dexamethasone | 15 | $257 | $17 |
| Ciclopirox | 11 | $134 | $12 |
| Sertraline | 12 | $76 | $6 |
2018: 13 drugs
| Imatinib Mesylate | 26 | $268,706 | $10,335 |
| Zytiga | 20 | $216,720 | $10,836 |
| Imbruvica | 12 | $142,456 | $11,871 |
| Tarceva | 11 | $85,142 | $7,740 |
| Entecavir | 14 | $11,234 | $802 |
| Exemestane | 17 | $9,971 | $587 |
| Oxycodone | 26 | $972 | $37 |
| Anastrozole | 70 | $755 | $11 |
| Prednisone | 27 | $261 | $10 |
| Ondansetron | 17 | $141 | $8 |
| Dexamethasone | 12 | $110 | $9 |
| Escitalopram | 11 | $48 | $4 |
| Furosemide | 18 | $43 | $2 |
2017: 13 drugs
| Imatinib Mesylate | 25 | $257,312 | $10,292 |
| Revlimid | 18 | $235,741 | $13,097 |
| Ibrance | 15 | $173,979 | $11,599 |
| Zytiga | 11 | $108,252 | $9,841 |
| Exemestane | 14 | $12,504 | $893 |
| Entecavir | 12 | $9,847 | $821 |
| Lamivudine Hbv | 12 | $2,763 | $230 |
| Anastrozole | 47 | $677 | $14 |
| Oxycodone | 18 | $462 | $26 |
| Letrozole | 15 | $130 | $9 |
| Dexamethasone | 12 | $118 | $10 |
| Amlodipine Besylate | 12 | $78 | $7 |
| Furosemide | 12 | $21 | $2 |
2016: 8 drugs
| Revlimid | 17 | $205,512 | $12,089 |
| Ibrance | 14 | $147,462 | $10,533 |
| Tarceva | 12 | $77,131 | $6,428 |
| Entecavir | 14 | $12,345 | $882 |
| Levothyroxine | 13 | $281 | $22 |
| Anastrozole | 13 | $216 | $17 |
| Dexamethasone | 12 | $55 | $5 |
| Hydroxyzine | 11 | $48 | $4 |
2015: 4 drugs
| Tarceva | 13 | $77,846 | $5,988 |
| Lamivudine Hbv | 31 | $11,289 | $364 |
| Emend | 11 | $11,054 | $1,005 |
| Ondansetron | 21 | $442 | $21 |
2014: 8 drugs
| Tarceva | 13 | $72,968 | $5,613 |
| Baraclude | 18 | $21,645 | $1,202 |
| Enoxaparin | 20 | $12,475 | $624 |
| Lamivudine Hbv | 29 | $10,500 | $362 |
| Anastrozole | 12 | $148 | $12 |
| Terazosin | 13 | $131 | $10 |
| Finasteride | 11 | $116 | $11 |
| Amlodipine Besylate | 12 | $33 | $3 |
2013: 5 drugs
| Tarceva | 12 | $62,263 | $5,189 |
| Baraclude | 16 | $16,112 | $1,007 |
| Terazosin | 11 | $113 | $10 |
| Amlodipine Besylate | 12 | $74 | $6 |
| Metoprolol | 11 | $51 | $5 |
Money from drug and device companies
$2,547 in 2025
| 2025 | 32 | 84 | None | $2,547 |
| 2024 | 1 | 1 | None | $86 |
| 2021 | 2 | 5 | None | $85 |
| 2020 | 3 | 4 | None | $257 |
| 2019 | 1 | 1 | None | $25 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $446 | 12 payments
|
| Novartis Pharmaceuticals | Kisqali | $225 | 7 payments
|
| Janssen Biotech | Tecvayli | $190 | 7 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $137 | 6 payments
|
| Celgene | Opdivo | $126 | 3 payments
|
| Organon | Vtama | $110 | 1 payment
|
See all 83 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-16 | Calquence | $30 |
| Pfizer | Meals · 2025-12-12 | Elrexfio | $25 |
| Abbvie | Meals · 2025-12-11 | Epkinly | $41 |
| Genmab U.S. | Meals · 2025-12-11 | Epkinly | $16 |
| Rigel Pharmaceuticals | Meals · 2025-12-11 | Tavalisse | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-08 | Opdivo | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-03 | Enhertu | $17 |
| Janssen Biotech | Meals · 2025-12-02 | Tecvayli | $30 |
| Janssen Biotech | Meals · 2025-12-01 | Tecvayli | $2 |
| Novartis Pharmaceuticals | Meals · 2025-12-01 | Kisqali | $34 |
| Caris MPI | Meals · 2025-11-24 | Mi Cancer Seek | $24 |
| Adc Therapeutics America | Meals · 2025-11-21 | Zynlonta | $35 |
| Abbvie | Meals · 2025-11-20 | Imbruvica | $28 |
| Abbvie | Meals · 2025-11-20 | Venclexta | $19 |
| Rigel Pharmaceuticals | Meals · 2025-11-19 | Tavalisse | $25 |
| GlaxoSmithKline | Meals · 2025-11-11 | Blenrep | $23 |
| Daiichi Sankyo | Meals · 2025-11-10 | Datroway | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-03 | Opdivo | $2 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-03 | Opdivo | $30 |
| BeOne Medicines USA | Meals · 2025-10-28 | Brukinsa | $30 |
| Novartis Pharmaceuticals | Meals · 2025-10-27 | Kisqali | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-21 | Opdivo | $35 |
| Incyte | Meals · 2025-10-20 | Monjuvi | $25 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Pluvicto | $24 |
| Novartis Pharmaceuticals | Meals · 2025-10-13 | Kisqali | $34 |
| Gilead Sciences | Meals · 2025-10-08 | Trodelvy | $20 |
| Novocure | Meals · 2025-10-07 | Optune Gio | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-06 | Opdivo | $17 |
| Pfizer | Meals · 2025-09-30 | Xtandi | $28 |
| Regeneron Healthcare Solutions | Meals · 2025-09-29 | Libtayo | $40 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Calquence | $29 |
| Incyte | Meals · 2025-09-16 | Monjuvi | $29 |
| Stemline Therapeutics | Meals · 2025-09-15 | Orserdu | $36 |
| Geron | Meals · 2025-09-12 | Rytelo | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-09 | Enhertu | $29 |
| Adc Therapeutics America | Meals · 2025-09-08 | Zynlonta | $39 |
| Merck Sharp & Dohme | Meals · 2025-09-02 | Keytruda | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-26 | Enhertu | $29 |
| Novocure | Meals · 2025-08-25 | Optune Lua (Novottf-200t) | $17 |
| Kite Pharma | Meals · 2025-08-19 | Yescarta | $15 |
| Kite Pharma | Meals · 2025-08-19 | Yescarta | $23 |
| Astellas Pharma US | Meals · 2025-08-18 | Xtandi | $24 |
| Merck Sharp & Dohme | Meals · 2025-08-12 | Keytruda | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-29 | Tagrisso | $37 |
| Daiichi Sankyo | Meals · 2025-07-28 | Datroway | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-21 | None | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Calquence | $20 |
| Janssen Biotech | Meals · 2025-07-15 | Carvykti | $40 |
| Merck Sharp & Dohme | Meals · 2025-07-08 | Keytruda | $31 |
| Caris MPI | Meals · 2025-07-01 | Mi Cancer Seek | $21 |
| Janssen Biotech | Meals · 2025-06-30 | Tecvayli | $37 |
| Janssen Biotech | Meals · 2025-06-29 | Tecvayli | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-23 | Fruzaqla | $34 |
| Novartis Pharmaceuticals | Meals · 2025-06-16 | Kisqali | $33 |
| Jazz Pharmaceuticals | Meals · 2025-06-03 | Ziihera | $39 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-02 | Enhertu | $34 |
| Celgene | Meals · 2025-05-27 | Opdivo | $28 |
| Geron | Meals · 2025-05-20 | Rytelo | $28 |
| Janssen Biotech | Meals · 2025-05-19 | Erleada | $39 |
| Daiichi Sankyo | Meals · 2025-05-12 | Enhertu | $23 |
| Novocure | Meals · 2025-05-12 | Optune Lua (Novottf-200t) | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-06 | Enhertu | $123 |
| Astellas Pharma US | Meals · 2025-05-06 | Xtandi | $23 |
| Celgene | Meals · 2025-05-05 | Opdivo | $65 |
| Regeneron Healthcare Solutions | Meals · 2025-04-28 | Libtayo | $38 |
| Organon | Meals · 2025-04-23 | Vtama | $110 |
| Tempus AI | Meals · 2025-04-23 | Xt Cdx | $36 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Kisqali | $34 |
| Lilly USA | Meals · 2025-04-21 | Verzenio | $33 |
| Taiho Oncology | Meals · 2025-04-08 | Lonsurf | $45 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-18 | Fruzaqla | $29 |
| Galderma Laboratories L.P. | Meals · 2025-03-12 | Nemluvio | $33 |
| Astellas Pharma US | Meals · 2025-03-08 | Xtandi | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-03 | Enhertu | $33 |
| Novartis Pharmaceuticals | Meals · 2025-02-25 | Pluvicto | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-24 | Calquence | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-19 | Enhertu | $34 |
| GlaxoSmithKline | Meals · 2025-02-13 | Ojjaara | $28 |
| Janssen Biotech | Meals · 2025-02-12 | Tecvayli | $40 |
| Celgene | Meals · 2025-02-10 | Opdivo | $34 |
| Incyte | Meals · 2025-02-03 | Niktimvo | $26 |
| Adaptive Biotechnologies | Meals · 2025-01-29 | Clonoseq | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-12 | Nubeqa | $22 |
See earlier years (2024, 2021, 2020, 2019)
2024: $86
| Abbvie | Rinvoq | $86 | 1 payment
|
2021: $85
| Pfizer | Ibrance | $71 | 4 payments
|
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
2020: $257
| Pfizer | Inlyta | $214 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $27 | 1 payment
|
| Ferring Pharmaceuticals | Clenpiq | $16 | 1 payment
|
2019: $25
| E.R. Squibb & Sons L.L.C. | None | $25 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment To Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib · 2024 | Their institution | $10,000 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568577906
- Licence
- CA A76724California A76724: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A767240
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-19
- NPI last updated
- 2025-03-05
- NPI record certified
- 2025-03-05
This is when the NPI record was last certified, not a medical board exam.